{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:56:52Z","timestamp":1777859812063,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Purpose: The manufacturer of sofosbuvir\/velpatasvir recommends avoiding coadministration with proton pump inhibitors (PPI) due to decreased velpatasvir serum concentrations which could translate to an increased risk of HCV treatment failure. A recent open-label study in healthy adults reported overcoming this interaction through co-administration of velpatasvir and a PPI with soda, but there is no clinical outcome data in HCV-infected patients. Summary: A 64\u00a0year-old male with a past medical history significant for decompensated cirrhosis, chronic HCV infection, upper gastrointestinal bleed, anemia, esophagitis, and previous HCV treatment failures required HCV treatment. The patient\u2019s medications included a PPI but no other significant DDI were present. The patient was instructed to take one sofosbuvir\/velpatasvir tablet, soda, and pantoprazole 40\u00a0mg tablet at the same time once daily. Treatment was well tolerated, and clinical cure of HCV was achieved. Conclusion: Scenarios may arise during HCV treatment that necessitate coadministration of a PPI. Interfering with optimal absorption of HCV treatment could lead to development of resistance or treatment failure. Future studies should include this strategy for overcoming this common DDI. This case demonstrates sofosbuvir\/velpatasvir administered orally with soda and a PPI is potentially safe and effective for treatment of chronic HCV infection.<\/jats:p>","DOI":"10.1177\/08971900231183036","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T16:59:35Z","timestamp":1688144375000},"page":"1011-1014","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Administering a Soda Beverage With the Hepatitis C Treatment Sofosbuvir\/Velpatasvir and the Proton-Pump Inhibitor Pantoprazole: A Case Report"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5957-782X","authenticated-orcid":false,"given":"Jennifer E.","family":"Stark","sequence":"first","affiliation":[{"name":"Veterans Healthcare System of the Ozarks, Fayetteville, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarice M.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Veterans Healthcare System of the Ozarks, Fayetteville, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"bibr1-08971900231183036","volume-title":"Epclusa (Sofosbuvir\/velpatasvir) [package Insert]","year":"2022"},{"key":"bibr2-08971900231183036","unstructured":"US Food and Drug Administration (FDA). Epclusa: Chemistry Review(s). US Food and Drug Administration: Washington, DC. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208341Orig1s000ChemR.pdf (June 2020)."},{"key":"bibr3-08971900231183036","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1569"},{"key":"bibr4-08971900231183036","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016670414"},{"key":"bibr5-08971900231183036","unstructured":"AASLD- IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. Wolters Kluwer, Inc: Philadelphia, PA. http:\/\/www.hcvguidelines.org (Accessed on October 15, 2022)."},{"key":"bibr6-08971900231183036","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis \u2013 Hepatitis C Information. US Departement for Health and Human Services: Washington, DC. http:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm#a4 (Accessed on October 1, 2022)."},{"key":"bibr7-08971900231183036","volume-title":"Non-adherance Is the Most Important Risk Factor for Ledipasvir\/sofosbuvir HCV Treatment Failure in the Real World","author":"Sarpel D","year":"2016"},{"key":"bibr8-08971900231183036","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1671"},{"key":"bibr9-08971900231183036","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04332.x"},{"key":"bibr10-08971900231183036","doi-asserted-by":"publisher","DOI":"10.1016\/j.adaj.2015.10.019"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900231183036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900231183036","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900231183036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:38:11Z","timestamp":1777509491000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900231183036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1177\/08971900231183036"],"URL":"https:\/\/doi.org\/10.1177\/08971900231183036","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}